A cheery reminder from David Leonhardt that not all vaccines are created equal, but in the case of COVID they’re equal enough. Consider this a gloss on Friday’s post about the “disappointing” Johnson & Johnson vaccine. It may not be as effective as Pfizer’s or Moderna’s but it’s performed just as well as those two in clinical trials at its core task, which is keeping people alive.
Same goes for Novavax and AstraZeneca, the other two vaccines to have completed phase three trials. Across all five, in a population of trial subjects the size of a small city, there wasn’t a single death from COVID.
Which is not to say that no one in the real world who’s received both doses has died of the disease. More on that in a moment.